Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Adjuvanted recombinant protein-based COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 11, 2020

            Details:

            In a phase I/II study of Sanofi/GSK’s adjuvanted recombinant protein-based vaccine, interim results found the vaccine induced an immune response comparable to recovered COVID-19 patients in adults aged 18 to 49 years.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Adjuvanted COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Gavi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 28, 2020

            Details:

            Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Adjuvanted COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Union

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 18, 2020

            Details:

            Agreement supports scale-up of manufacturing capabilities in several European countries . The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Adjuvanted COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 03, 2020

            Details:

            The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.S Department of Health and Human Services

            Deal Size: $2,100.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration July 31, 2020

            Details:

            Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi’s and GSK’s manufacturing capabilities in the U.S for the recombinant protein-based, adjuvanted vaccine.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Union

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 31, 2020

            Details:

            The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: UK government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 29, 2020

            Details:

            The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VLA2001,CpG 1018

            Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 16, 2020

            Details:

            VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.